Ajanta Pharma stock tumbles 1% after USFDA issues form 483 to Dahej facility

12 Sep 2022 , 01:34 PM

Ajanta Pharma Limited stock tumbles nearly 1% on Monday’s trading session after it informed to the exchanges regarding USFDA inspection of Company’s Dahej facility.

In a regulatory filing, the company informed that its formulation facility at Dahej was inspected by USFDA from September 05, 2022 to September 09, 2022.

At the end of the inspection, Form 483 was issued with 2 procedural observations, the company said.

In addition to this, “We are in the process of responding to the same within the stipulated time prescribed by US FDA”, it added.

On Monday, at around 1:35 PM, Ajanta Pharma Ltd is currently trading at Rs1,382.20 per share down by Rs12.9 or 0.92% from its previous closing of Rs1,395.10 per share on the BSE.

The scrip opened at Rs1,400 per share and has touched a high and low of Rs1,400 per share and Rs1,362 per share respectively so far today. The current market cap of the company is Rs17,874.74 crore.

For feedback and suggestions, write to us at [e-mail]